EDGAR·FLOW

iBio, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 28/100
What the filing says
iBio announced preclinical data for IBIO-610 (Activin E antibody) presented at ObesityWeek 2026, showing sustained Activin E suppression and 2.3% vehicle-adjusted body weight reduction at week 28 in obese non-human primates (n=5 treated, n=6 vehicle), plus 9.6% lower total body fat and 16.6% lower abdominal subcutaneous fat at week 24. The company also reported amylin program data demonstrating selective receptor binding and reduced food intake in rats, to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit.
Why this rating

Early preclinical data supports pipeline but no clinical trials, regulatory approval, or partnerships announced. At $57.5M market cap, positive poster data is routine; material only if advancing to human trials.

View original filing on SEC.gov ↗ IBIO · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.